A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
INmune Bio Inc. (INMB) is a company in the Health care sector; its shares trade on Nasdaq.
The price of INmune Bio Inc. (INMB) on November 18, 2026 is $1.02, +6.25% on the day. Over 52 weeks the stock traded between $0.8934 and $2.60; the price now sits 7% of the way up that range. Over the past year the price changed by −28.17%. Market capitalisation is $26.85 million, rank 104 among 133 stocks of the same industry with a known capitalisation.
INmune Bio Inc. trades on Nasdaq under the ticker INMB. The company belongs to the Health care sector. The trading history on this page starts on 4 February 2019.
Over the past 52 weeks INMB has traded between $0.8934 and $2.60. As of 18 November 2026 the price stood 7.42% of the way from the 52-week low to the high.
Over one year INMB shares fell 33.35%; over six months they fell 36.48%. Volatility over 90 days is 71.54%. Dividends are not included: this is price change only, as of 18 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 537, above the sector median of 3.5. Price to book is 1.3, below the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
INMB has a return on equity of −90.44%, below the sector median of −40.58%. Return on assets is −68.60%, below the sector median of −30.08%.